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Abstract
Objective
To describe the clinical and pathologic features of a novel pedigree with heterozygous STUB1
mutation causing SCA48.
Methods
We report a large pedigree of Dutch decent. Clinical and pathologic data were reviewed, and
genetic analyses (whole-exome sequencing, whole-genome sequencing, and linkage analysis)
were performed on multiple family members.
Results
Patients presented with adult-onset gait disturbance (ataxia or parkinsonism), combined with
prominent cognitive decline and behavioral changes. Whole-exome sequencing identified
a novel heterozygous frameshift variant c.731_732delGC (p.C244Yfs*24) in STUB1 segre-
gating with the disease. This variant was present in a linkage peak on chromosome 16p13.3.
Neuropathologic examination of 3 cases revealed a consistent pattern of ubiquitin/p62-positive
neuronal inclusions in the cerebellum, neocortex, and brainstem. In addition, tau pathology was
present in 1 case.
Conclusions
This study confirms previous findings of heterozygous STUB1mutations as the cause of SCA48
and highlights its prominent cognitive involvement, besides cerebellar ataxia and movement
disorders as cardinal features. The presence of intranuclear inclusions is a pathologic hallmark
of the disease. Future studies will provide more insight into its pathologic heterogeneity.
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Spinocerebellar ataxias (SCAs) comprise a heterogeneous
group of disorders characterized by progressive cerebellar
ataxia in combination with noncerebellar signs, including
(extra) pyramidal features, peripheral neuropathy, and cog-
nitive impairment.1 In most cases, prominent loss of cere-
bellar Purkinje neurons is observed, yet neuropathologic
changes can be diverse with degeneration extending to all
brain areas. Frequently, intranuclear neuronal inclusions serve
as a morphologic marker.2
Currently, over 40 autosomal dominant SCAs have been
identified.1 Polyglutamine SCAs caused by trinucleotide CAG
repeat expansion represent the most common form. Other
genetic causes include repeat expansion in noncoding regions
and conventional mutations.3 A large percentage of patients
with familial SCA (30%–48%) remain without an identified
genetic defect.4 In the past decade, an increasing number of
rare causal variants have been recognized in both dominant
and recessive forms of ataxia.5 Among these are variants in
STUB1 (STIP1 homologous and U-box-containing protein 1;
OMIM#607207), the gene encoding the protein C-terminus
of Hsp70-interacting protein (CHIP). This molecular co-
chaperone plays a prominent role in protein quality control
processes and the cellular stress response.6 Recessive STUB1
mutations were identified in families with SCAR16, showing
a wide variability of symptoms, including hypogonadism,
epilepsy, autonomic dysfunction, and dementia.7,8 More re-
cently, heterozygous variants in STUB1 have been implicated
in autosomal dominant SCA (SCA48; OMIM#618093),
characterized by a complex phenotype including cognitive/
affective symptoms and movement disorders.9–12
In this study, we present a large Dutch SCA48 family asso-
ciated with a novel heterozygous frameshift mutation in the
U-box domain of STUB1 and describe the neuropathologic
features of 3 patients in this family.
Methods
Clinical data
Medical records and neuroimaging of 9 affected individuals
from 1 large family of Dutch ancestry were collected and
reviewed (figure 1 and table 1). Seven of them underwent
a single clinical assessment by neurologists from the re-
search group (E.B., J.C.v.S., and L.D.K.) during a local visit.
Blood samples were collected from 7 affected and 5 un-
affected family members; DNAwas extracted using standard
procedures.
Standard protocol approvals, registrations,
and patient consents
The study was approved by theMedical Ethical Committee of
the Erasmus Medical Center Rotterdam. Brain autopsy was
conducted by the Netherlands Brain Bank according to their
Legal and Ethical Code of Conduct. Written informed con-
sent was obtained from all participants and/or their legal
representatives.
Genetic studies
Linkage analysis
Single nucleotide polymorphism (SNP) array genotyping
(Illumina Human OmniExpress-24 v1.0 BeadChip) was
performed on 7 patients (III-8, III-9, III-10, III-11, III-12, III-
13, and IV-1). SNP call data were adapted by GenomeStudio
(Illumina) for linkage analyses using Allegro, implemented in
easyLINKAGE Plus.13,14 An affected-only linkage analysis was
performed. Mendelian inheritance check was performed with
the program PedCheck.15 SNPs showing mendelian incon-
sistencies were excluded from the calculations. Multipoint
linkage analysis was performed with an SNP spacing of 0.3
cM. Logarithm of the odds (LOD) scores were calculated
under the assumption of an autosomal dominant disorder.
Whole-exome and genome sequencing
Whole-exome sequencing (WES) was performed on the
same 7 patients as those included in the linkage analysis.
Whole-genome sequencing (WGS) was performed on 3 of
these patients (III-12, III-13, and IV-1). Genomic DNA was
fragmented to 150–200 base pairs (bp), end paired, ade-
nylated, and ligated to adapters. The SeqCap capturing kit
for Illumina Paired-End Sequencing Library (version 2.0.1;
NimbleGen) was used. The captured fragments were puri-
fied and sequenced on an Illumina Hiseq2000 platform
using 100 bp paired-end reads. WGS was performed by
Novogene on an Illumina Hiseq2000 platform using 150 bp
paired-end reads. Bioinformatic analysis was performed
using an in-house pipeline based on published tools. Briefly,
sequence reads were aligned to the human reference ge-
nome (hg19) using Burrows-Wheeler Aligner (version
0.7.3a).16 Subsequently, alignment data were processed and
recalibrated using Picard (version 1.90) and the Genome
Analysis Toolkit (GATK version 2.5.2). SNPs and small
indels were called using GATK’s HaplotypeCaller and
Variant recalibration following best practices.17 The WES
and WGS data sets were generated separately. The lists of
variants from the WES data were annotated with Annovar18
and filtered to include (1) exonic and splice site variants, (2)
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nonsynonymous, (3) with rare occurrence in publicly
available databases (1000G, Exome Aggregation Consor-
tium and Exome Sequencing Project; minor allele frequency
<0.1%), and (4) QD score >5 (quality score normalized by
allele depth). Functional predictions by Sorting Intolerant
From Tolerant and/or PolyPhen-2 were taken into account.
In addition, to detect the possible presence of expanded
polyglutamine repeats, short tandem repeats (STRs) were
called using WGS data in the chr16p13.3 linkage peak using
LobSTR (v3.0.3) according to best practices.19 STRs were
filtered for heterozygosity in all 3 carriers. The repeat motif
and number of copies per carrier were extracted and ana-
lyzed manually. RefSeq gene annotation was added using
Annovar (ref; 20601685). The candidate variant was
checked by Sanger sequencing (details provided in sup-
plementary file, links.lww.com/NXG/A251).
Neuropathology
Three patients died during follow-up (III-10, III-12, and III-
13); brain autopsy was performed by the Netherlands Brain
Bank within 4 hours after death. Formalin-fixed (10%) and
paraffin-embedded tissue blocks were available for exami-
nation. Eight-micrometer sections of all cortical regions,
subcortical nuclei, brainstem, and cerebellum underwent
routine staining. Immunohistochemistry was performed
using the following antibodies: hyperphosphorylated tau
(AT8, Innogenetics, Ghent, Belgium; 1:40), beta-amyloid
(anti-amyloid, DAKO, Glostrup, Denmark; 1:100, following
formic acid pretreatment), alpha-synuclein (anti-synuclein,
Zymed Laboratories, San Francisco, CA; undiluted, follow-
ing formic acid pretreatment), TDP-43 (anti-phospho TDP-
43, Cosmo Bio, 1:100 and Proteintech Group, 1:100),
ubiquitin (anti-ubiquitin, DAKO, Glostrup, Denmark; 1:
500, following 80°C antigen retrieval), p62 (mouse D3
Clone, Santa Cruz, 1:100), 1C2 (mouse 5TF1-1C2-172
Clone, Chemicon, 1:3,200), and STUB1 (rabbit anti-
STUB1 Abcam ab2917, 1:100).
Data availability
The deidentified data generated and analyzed in the current
study will be available and shared by request to the corre-
sponding author (M.O.M.) from any qualified investigator.
These data include deidentified clinical data, raw exome/
genome files, microsatellite genotyping, and additional pic-
tures of stainings from the studied material.
Results
Clinical characteristics
The pedigree structure is presented in figure 1, and the main
clinical features of 9 affected individuals are summarized in
table 1. Individuals II-2, II-3, III-1, III-2, III-3, III-5, and III-6
were deceased before the start of the study, and DNA was not
available. Patient III-4 was not included in the genetic analyses
(linkage and WES) because the clinical signs did not fully
match with the other family members (i.e., isolated cognitive
dysfunction suggestive of Alzheimer disease [AD] without
ataxia or movement disorders). Mean age at onset of disease
in the 9 patients was 65.3 ± 6.6 years. These patients deceased
after a mean disease duration of 13.2 ± 2.4 years. The pre-
senting features consisted of slowly progressive gait distur-
bance (mainly ataxic and frequently described as a waddled
gait) combined with prominent cognitive dysfunction and
behavioral changes with impaired insight, disinhibition, and
perseverations. The cognitive deficits were among the first
symptoms in some patients, showing a gradual decline in
memory performance and executive functioning. Imaging in
6 of 9 patients showed cerebellar atrophy; 2 had moderate
Figure 1 Pedigree of the family
Filled black symbols represent patients who were personally examined by the researchers. Filled gray symbols are affected individuals based on medical
records (III-2 and III-3) or on reports from family members (II-2, III-1, III-5, and III-6). Individuals III-7, III-14, III-15, III-16, and III-17 were clinically unaffected and
all deceased >75 years of age. Individual II-3 is an obligate carrier but did not have neurologic symptoms according to the family. Individual III-4 was diagnosed
with Alzheimer disease without motor symptoms and without cerebellar atrophy and not considered to have the same phenotype. The numbers inside the
symbols represent the number of individuals. Sex is not specified to protect anonymity. Transmission was independent of sex (including male to male
transmission). + = mutated allele; – = wild type.
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to severe generalized atrophy (for 1 patient, no scan was
available). Initial clinical diagnoses by reviewing medical
records were olivopontocerebellar atrophy, Huntington dis-
ease (without genetic confirmation), unspecified chorea,
progressive supranuclear palsy (PSP), AD, frontotemporal
dementia (FTD), and unspecified dementia.
Two patients are further described in more detail: patient III-
10 presented at age 65 years with a parkinsonian gait, frequent
falls, and bradykinesia unresponsive to levodopa. Sub-
sequently, memory problems developed together with be-
havioral changes and impulsiveness. On neurologic
examination, dysarthria, an upward gaze palsy, bilateral bra-
dykinesia, a shuffling gait with freezing, and abnormal postural
reflexes were found. Neuroimaging with MRI showed gen-
eralized atrophy, including cerebellar volume loss. This pa-
tient died 18 years after disease onset at age 83 years.
Patient III-13 presented with progressive behavioral changes
from age 50 years, including inappropriate laughing, aggres-
siveness, and perseverations. Neurologic examination
revealed dysarthria, diffuse motor restlessness, and stereotypic
movements. Neuropsychological evaluation indicated
pronounced frontal symptoms and semantic deficits, but with
preservation of episodic memory. On MRI, severe cerebellar
and bilateral parietal atrophy was observed. The hippocam-
pus, frontal, and temporal lobes showed no apparent de-
generation. This patient died after a disease duration of 14
years.
Genetic analyses
Diagnostic testing excluded mutations in MAPT, C9orf72,
PSEN1, PRNP, HTT, DRPLA, FMR1, SCA1, SCA2, SCA3,
SCA6, SCA7, and SCA17. Genome-wide linkage analysis
using SNP array data did not reveal a significance linkage
peak (LOD score >3). However, a few regions showed
suggestive linkage, including the region on chromosome
16p13.3 with an LOD score of 2.35. After filtering, WES data
of 7 patients revealed 5 candidate variants, all of them in the
heterozygous state and located on chromosome 16p13.3.
These included 4 nonsynonymous missense variants
(AXIN1, IGFALS, PDK1, and THOC6) and 1 frameshift
variant (STUB1). Analysis of WGS data of 3 patients using
the same filtering steps confirmed these 5 variants; no ad-
ditional variants were found. In these patients, LobSTR was
used on the chromosome 16p13.3 linkage area to identify
Table Summary of demographic and clinical data of affected individuals
Patient AAO DD AAD
Clinical features
Imaging
Initial
diagnosis Cognitive/behavioral symptomsCI D G UL SP GP P Ch
III-2 71 13 84 ± ? + ? ? ? − + NA Huntington Social withdrawal, perseverance
III-3 66 14 80 + + + + ? ? ? + CAa Huntington Intellectual disability since birth
III-8 72 14 86 + + ± − + − − − CA and
GAb
AD Memory deficits, impaired language
comprehension, disorientation,
perseverance, and irritability
III-9 69 14 83 + + + − + − − − CAa OPCA Memory deficits, apraxia,
disorientation, perseverance, and
mental speed decline
III-10c 65 18 83 + + − − + + + − CA and
GAb
PSP Memory deficits, impulsiveness, and
disinhibition; MMSE 24/30, FAB 7/18
III-11 67 11 78 + + ± ± − − − − GAa Dementia
NOS
Perseverance, apraxia, executive
dysfunction, disinhibition, and lack of
insight
III-12c 61 10 71 + + ± − − + ± ± CAa SCA,
dementia
Memory deficits, passivity, impaired
language comprehension, and lack of
insight
III-13c 50 14 64 + + + − − + − ± CAb FTD Childish behavior, inappropriate
laughing, disinhibition, perseverance,
and aggressiveness
IV-1 67 11 78 + ± + ± + + ± ± GAa Dementia
NOS
Memory deficits, impulsiveness,
executive dysfunction, and lack of
insight; MMSE 20/30, FAB 5/18
Abbreviations: AAO = age at first symptom onset; AAD = age at death; DD = disease duration; FAB = frontal assessment battery; FTD = frontotemporal
dementia; MMSE = Mini-Mental State Examination. Clinical symptoms: CI = cognitive impairment; Ch = chorea/motoric restlessness; D = dysarthria; G = gait
ataxia; GP = gaze palsy; P = parkinsonism; SP = saccadic pursuit; UL = upper limb ataxia; − = absent; ± = subtle; + = present; ? = unknown. Imaging: CA =
cerebellar atrophy;GA = generalized atrophy;NA =not available. Diagnosis: AD=Alzheimer disease; DementiaNOS =dementia not otherwise specified; OPCA
= olivopontocerebellar atrophy; PSP = progressive supranuclear palsy; SCA = spinocerebellar ataxia.
a CT imaging.
b MR imaging.
c Pathologic examination.
4 Neurology: Genetics | Volume 6, Number 3 | June 2020 Neurology.org/NG
possible expanded polyglutamine repeats, but none were
detected.
Of these 5 candidates, the frameshift variant in STUB1 is the
most likely candidate because this gene has recently been
linked to both recessive (SCAR16) and dominant ataxia
(SCA48). The 2-bp deletion c.731_732delGC
(p.C244Yfs*24) is located in exon 6, which encodes the U-box
domain together with the last exon. This variant is absent in
publicly available databases, and Sorting Intolerant From
Tolerant predicts a damaging effect (confidence score 0.86).
The mutation was confirmed by Sanger sequencing (figure
e-1, links.lww.com/NXG/A251). Subsequently, 5 unaffected
relatives were tested (III-7, III-14, III-15, III-16, and III-17),
and in 4 of 5, the variant was absent. Individual III-4, who was
not considered to have the same phenotype, did not have the
STUB1 variant. There was no report of neurologic symptoms
in individual II-3, who is an obligate carrier of the STUB1
variant, but died at age 64 years due to a myocardial infarction.
Neuropathology
Neuropathologic examination was performed in 3 patients
(III-10, III-12, and III-13). Brain weight varied slightly (1,304,
1,223, and 1,090 g, respectively). Macroscopic inspection
showed cerebellar atrophy of vermis and hemispheres in all 3
cases, although less profound in III-10. Routine staining on
the 3 brains showed no abnormalities in cortical areas, except
for focal neuron loss in the parietal and occipital cortices in
III-13. Cases III-12 and III-13 contained no apparent hippo-
campal plaques or tangles (Braak stage 1), whereas a few
tangles and neuropil threads were seen in the Ammon horn in
III-10 (Braak stage 2). All 3 cases showed nearly complete loss
of Purkinje cells with Bergmann gliosis (figure 2A) and severe
neuronal loss in the mesencephalon and medulla oblongata.
In III-10, the subthalamic nucleus also showed atrophy with
severe gliosis. Staining of the cerebellum of III-13 with
ubiquitin showed several neuronal intranuclear inclusions
(NIIs) in cerebellar granular cells (figure 2C). In all 3 cases,
immunohistochemistry with p62 showed similar NII in the
cerebellum (figure 2D) and in all cortical areas, most preva-
lent in posterior regions (figure 2E). NIIs were also present in
the substantia nigra and deep pontine nuclei. In the hippo-
campus, many p62-positive inclusions were found, whereas
the dentate gyrus showed punctuate cytoplasmic inclusions
(CIs) and occasional diffuse nuclear staining (DNS). Staining
with 1C2 antibody in III-13 showed DNS in granular and
stellate neurons of the cerebellum and in cortical areas (figure
2F). In the substantia nigra, CIs were observed, and the gyrus
cinguli showed CI, DNS, and dystrophic neurites. 1C2
staining also exposed DNS in the inferior olives (figure 2G)
and CI in the hypoglossal nucleus with a granular pattern
(figure 2H). In III-10, faint 1C2 reactivity was seen in the
cerebellum, less prominent than with p62. In cortical regions,
similar DNS was seen as in III-13. 1C2 staining was not
performed in III-12. Staining with the antibody against CHIP
in III-13 showed a diffuse staining of neurons, not different
from controls (data not shown). AT8 staining in cases III-12
and III-13 showed few abnormalities, except for a few positive
neurons in the temporal neocortex (III-12) and a moderate
number of pretangles (III-13). Of interest, AT8 staining in
III-10 showed many tufted astrocytes, glial staining, and
tangles in the thalamus and subthalamic nucleus (figure 2I).
Tau pathology was also present in many other regions
(i.e., temporal cortex (figure 2J), hippocampus, caudate,
putamen, substantia nigra, locus coeruleus, cerebellar dentate
nucleus, and spinal motor neurons). Immunohistochemistry
for alpha-synuclein and TDP-43 antibodies in several selected
brain regions was negative in all 3 cases.
Discussion
We present a multigenerational family with late-onset ataxia
associated with a novel heterozygous STUB1mutation, fitting
the diagnosis of SCA48. Although the various initial diagnoses
of the patients illustrate the clinical heterogeneity of this new
SCA subtype, there are some strongly overlapping features.
The clinical presentation is dominated by cognitive decline
and profound behavioral changes, combined with cerebellar
ataxia and movement disorders.
Cognitive impairment has been found in other SCA subtypes,
but is usually preceded by cerebellar symptoms.20 Here, it was
present in all affected family members and occasionally as the
first manifestation. One case was initially diagnosed as FTD,
although frontal and temporal atrophy were lacking. Other
published SCA48 pedigrees with mutations in close proximity
to the current mutation showed a broad range of cognitive
symptoms.9–12 Another interesting observation is the pres-
ence of other movement disorders besides gait ataxia. Chorea
or uncontrolled motor activity was frequently reported,
showing resemblance with the chorea described in several
other families.10–12 Parkinsonism was also present in 4 of 11
described Italian patients with SCA48.11 Atypical parkinson-
ism with features resembling PSP was observed in 1 pa-
tient. The combination of cognitive and movement disorders
in SCA48 also resembles SCA17 and dentatorubral-
pallidoluysian atrophy. In both disorders, dementia and
chorea are part of the clinical features.1,21
The clinical presentation of SCA48 shows overlap with
SCAR16. The latter is more complex with a myriad of phe-
notypes and seems to constitute a multisystemic disorder
usually presenting at an earlier age.7,22 Endocrine abnormal-
ities have been described as a major feature of SCAR16, and
hypogonadism was present in patients with SCA48.11 Al-
though not formally tested, endocrine abnormalities were not
reported in the medical records of the current pedigree.
The homozygous and compound heterozygous STUB1
mutations in SCAR16, and the recent identification of het-
erozygous STUB1 mutations in adult-onset familial ataxia,
support STUB1 as the most likely candidate gene in this
family. The identified frameshift variant is predicted to result
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in a premature stop codon and is located in the highly con-
served U-box domain, similar to previously reported variants
causing SCAR16 and SCA48.8,9,11,23 The protein encoded by
STUB1, CHIP, regulates several proteins involved in neuro-
degenerative disorders.6 Through its tetratricopeptide repeat
domain, CHIP interacts with chaperones (Hsp70 andHsp90)
and a broad range of co-chaperones. The ubiquitin ligase
region (U-box) is responsible for the ubiquitination of mis-
folded proteins destined for elimination.24 Missense muta-
tions in the U-box domain of CHIP impair the intracellular
degradation of ataxin-3 microaggregates by preventing their
ubiquitination, thereby accelerating disease progression.25We
hypothesize that a similar pathophysiologic mechanism is
likely in SCA48 due to impaired function of CHIP.
Figure 2 Histopathologic features of affected cases III-13 (A–H) and III-10 (I and J)
(A and B) Nearly complete loss of Purkinje cells,
loss of neurons, and spongiosis in the cerebellar
granular layer of the patient (A) compared with
the control brain (B) in H/E staining; (C and D) NII
in the cerebellar granular layer with ubiquitin (C)
and p62 staining (D); (E) NII in the occipital cortex
with p62 staining; (F) DNS in the occipital cortex
with 1C2 staining; (G) DNS in the inferior olive
with 1C2 staining; (H) granular CI in the hypo-
glossal nucleus with 1C2 staining; (I) AT8-positive
neurons, neurites, and glial staining in the tha-
lamic nuclei; (J) AT8-positive tufted astrocyte in
the putamen. The arrowheads indicateNII, which
are magnified in figure 2C-F. CI = cytoplasmic
inclusion; DNS = diffuse nuclear staining; H/E =
hematoxylin and eosin staining; NII = neuronal
intranuclear inclusion.
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Earlier work has shown that mutations in the U-box domain
causing SCAR16 destabilize CHIP, supporting a loss-of-
function mechanism.26 CHIP null mice and animal models
with homozygous missense mutation (p.T246M) exhibited
striking similarities with characteristics seen in SCAR16
patients, including neuronal degeneration and ataxic motor
disturbances.7,27 Patients with recessive STUB1mutations had
decreased CHIP protein levels in isolated fibroblasts in varying
degrees, dependent on specific mutations.27 The U-box do-
main is especially important, as mutations in this domain have
a stronger effect on the overall loss of CHIP function and
strongly associate with cognitive dysfunction.28 Indeed, most
frameshift mutations identified so far in SCA48 are located in
the U-box domain (table e-1, links.lww.com/NXG/A251).9,11
Whether this results in nonsense mediated RNA decay or
a truncated protein (with a possible dominant negative effect)
remains to be elucidated. Additional functional studies on dif-
ferent mutations in STUB1 are essential to provide more in-
sight why some mutations cause SCA48 in heterozygous state
and others SCAR16 in a recessive trait. The co-occurrence of
recessive and dominant mutations in the same gene has been
described before. For example, mutations in HTRA1 are re-
sponsible for cerebral autosomal recessive arteriopathy with
subcortical infarcts and leukoencephalopathy (CARASIL),
while heterozygous mutations causing a late-onset form of
small vessel disease have been reported.29 Likewise, truncating
heterozygous progranulin mutations cause FTD, whereas ho-
mozygous mutations lead to neuronal ceroid lipofuscinosis.30
In the current study, 2 carriers of the STUB1mutation did not
develop symptoms: 1 unaffected carrier died over age 75
years, and another (obligate) carrier died at age 64 years
without neurologic disease. This could indicate incomplete
penetrance, or it could reflect the diversity in phenotypical
expression, given the large variety in ages at onset in the
present family (50–72 years). Therefore, it cannot be ex-
cluded that parents of some patients with SCAR16 are at risk
of developing SCA48.
It would also be of interest to investigate other genetic factors
that could influence disease penetrance and progression.
Previous studies have shown that expanded ataxin-2 repeats
predispose to other neurodegenerative disorders besides
SCA2.31 In line with this, it would be interesting to explore
whether repeat length variation in ataxin-3, a known inter-
actor of CHIP, might interfere with the function of CHIP and
influence the clinical variability in SCA48. Although we have
not found toxic exposures in patients (data not shown), it is
worthwhile to study more systematically whether environ-
mental factors can trigger the unfolded protein response and
may therefore have an effect on disease onset or progression
in STUB1-related disorders.
Neuropathologic changes were present in cerebellar but also
neocortical areas, suggesting diffuse involvement of the brain.
The almost complete loss of Purkinje cells in the present 3
cases resembles that of most other SCAs.2 Neuropathologic
studies of other STUB1 cases are scarce, with a single neu-
ropathologic report of an SCAR16 patient.32 This case
showed similar severe Purkinje cell loss and p62-positive NIIs,
and CHIP staining revealed nuclear staining in neurons of the
deep layers of the frontal cortex. We also observed diffuse
staining of neurons with CHIP antibody, but not different
from controls (data not shown).
NIIs have been considered the hallmark of disorders with repeat
expansions.33 However, several studies have demonstrated the
presence of NIIs in the absence of pathologically expanded
polyglutamine repeats.34 Moreover, NIIs in the present cases did
not show 1C2 positivity, which is typically present in SCA caused
by polyglutamine repeat expansion.2 Instead, we did observe
a pattern of DNS with 1C2. Granular cytoplasmic and DNS of
1C2 as an earlier stage in aggregate formation have been de-
scribed in both SCA3 and Huntington disease.35 Other studies
have demonstrated that 1C2 recognizes nonexpanded ataxin-3
present inNIIs.36,37 It is possible that recruitment of ataxin-3 into
the nucleus is involved in the pathogenesis of STUB1 disease.38
Finally, 1C2 immunoreactivitymight be less specific, as it has also
been detected in nonrepeat disorder, such as a SCA6 case with
22–24 polyglutamine stretches39 and in healthy controls.40 Fu-
ture investigations are needed to clarify the exact meaning of the
different types of staining patterns on the cellular (dys)function.
Intriguingly, extensive tau pathology was found in 1 patient
with clinical similarities to PSP (III-10). This has up till now
only been seen in SCA11, a pure progressive cerebellar
ataxia.2 Several studies highlight the role of CHIP in tau pa-
thology. It attenuates the pathologic changes associated with
tau, playing a primary role in tau ubiquitination and degra-
dation.41 CHIP levels were found to be elevated in AD, sug-
gesting a role in tangle maturation,42 and CHIP depletion in
mice was associated with accumulation of hyper-
phosphorylated tau.43 The discovery of different pathologies
within 1 kindred is known to occur also in other (genetic)
neurodegenerative diseases.44
The present pedigree along with the recently described fam-
ilies underscores the association between heterozygous
STUB1 mutations and SCA48. The combination of familial
late-onset gait ataxia, cognitive decline with behavioral
changes, and other movement disorders (parkinsonism,
chorea, and stereotypic movements) is indicative of SCA48.
We show that the pathology of SCA48 is dominated by
Purkinje cell loss, p62-positive intranuclear inclusions, and
may also include tau pathology. Additional functional studies
and reports of newly identified SCA48 and SCAR16 families
will provide more insight into the heterogeneous spectrum of
STUB1-related disorders.
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